Gordana Vlahovic MD

Oncology•Durham, NC

Assistant Professor, Medicine, Duke University School of Medicine

Join to View Full Profile

40 Duke Medicine CirDurham, NC 27710
Phone+1 919-684-8111

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2000 - 2003
Duke University HospitalResidency, Internal Medicine, 1997 - 2000
University of Zagreb Faculty of MedicineClass of 1987

Certifications & Licensure

NC State Medical License 2001 - 2022

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer Start of enrollment: 2007 May 01
Terminated
Phase 2
Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia Start of enrollment: 2007 Apr 24
Completed
Phase 1
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2006 Feb 06
Completed
Phase 1
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2007 Sep 01
Completed
Phase 2
Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer Start of enrollment: 2008 Sep 01
Completed
Phase 1
Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme Start of enrollment: 2009 Sep 01
Completed
Phase 1
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma Start of enrollment: 2014 Jan 09
Terminated
Phase 1, Phase 2
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07
COMPLETED
PHASE3
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 Start of enrollment: 2004 Nov 01
Terminated
Phase 1, Phase 2
IDH1 Peptide Vaccine for Recurrent Grade II Glioma Start of enrollment: 2016 Jan 28
Completed
Phase 1
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Start of enrollment: 2015 Jan 01
Completed
Phase 1, Phase 2
EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma Start of enrollment: 2017 Feb 01
Terminated
Phase 1
Lerapolturev in Recurrent Malignant Glioma Start of enrollment: 2017 Jun 01
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.
Eric M Thompson, David M Ashley, Katayoun Ayasoufi, Pamela Norberg, Gerald Archer
Nature Cancer. 2025-09-01
499 citations
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Eileen M. O'Reilly, Do Youn Oh, Neesha C. Dhani, Daniel J. Renouf, Myung Ah Lee
JAMA Oncology. 2019-10-01
21 citations
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.
Yutaka Fujiwara, Haruo Iguchi, Noboru Yamamoto, Manabu Hayama, Masahiro Nii
Cancer Science. 2019-05-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member